Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Ryan White HIV/AIDS Program: Allocations Forms, 8295-8297 [2023-02686]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 26 / Wednesday, February 8, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
notice that the oncology drugs at issue
were unapproved and that the medical
practice discontinued ordering those
drugs when he learned of that regulatory
status, as discussed above, it is
undisputed that the offense to which he
pled guilty led to his administering
foreign, unapproved drug products to
his patients. Even assuming Dr.
Tahsildar’s representations with respect
to his reduced role as a manager in the
practice to be true, the Chief Scientist
also cannot conclude that his
managerial role is a favorable
consideration, given his status as a
partner and a physician in that practice.
Balancing the applicable
considerations—including his voluntary
steps in mitigation under section
306(c)(3)(C) of the FD&C Act and the
absence of previous criminal
convictions related to matters within the
jurisdiction of FDA under section
306(c)(3)(F)—the Chief Scientist has
determined that a 2-year debarment
period is appropriate. Inasmuch as there
are no material factual disputes for
resolution at a hearing, the Chief
Scientist is also denying Dr. Tahsildar’s
hearing request.
Separately, Dr. Tahsildar requests
that, in lieu of debarment by FDA, he
enter into a settlement agreement with
FDA whereby he would voluntarily
agree to the terms of the proposed
debarment for the proposed period of
debarment and to not provide services
in any capacity to a person that has an
approved or pending drug product
application. Dr. Tahsildar appears to be
proposing an informal resolution of this
debarment matter. However, his request
is now moot given that the foregoing
findings support debarment for a 2-year
period.
III. Findings and Order
Therefore, the Chief Scientist, under
section 306(b)(2)(B)(i)(I) of the FD&C
Act and authority delegated to her by
the Commissioner of Food and Drugs,
finds that Dr. Tahsildar has been
convicted of a misdemeanor under
Federal law for conduct related to the
regulation of drugs under the FD&C Act
and that the type of conduct underlying
the conviction undermines the
regulation of drugs. FDA has considered
the relevant factors listed in section
306(c)(3) of the FD&C Act and
determined that a 2-year debarment is
appropriate.
As a result of the foregoing findings,
Dr. Tahsildar is debarred for 2 years
from providing services in any capacity
to a person with an approved or
pending drug product application under
sections 505, 512, or 802 of the FD&C
Act (21 U.S.C. 355, 360b, or 382), or
VerDate Sep<11>2014
16:59 Feb 07, 2023
Jkt 259001
under section 351 of the Public Health
Service Act (42 U.S.C. 262), effective
February 8, 2023, (see 21 U.S.C.
335a(c)(1)(B) and (c)(2)(A)(iii) and 21
U.S.C. 321(dd))). Any person with an
approved or pending drug application
who knowingly uses the services of Dr.
Tahsildar, in any capacity during his
debarment, will be subject to civil
money penalties (section 307(a)(6) of the
FD&C Act (21 U.S.C. 335b(a)(6))). If Dr.
Tahsildar, during his period of
debarment, provides services in any
capacity to a person with an approved
or pending drug product application, he
will be subject to civil money penalties
(section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review
any abbreviated new drug applications
submitted by or with the assistance of
Dr. Tahsildar during his period of
debarment (section 306(c)(1)(B) of the
FD&C Act).
Dated: February 2, 2023.
Namandje´ N. Bumpus,
Chief Scientist.
[FR Doc. 2023–02634 Filed 2–7–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
[OMB No. 0915–0318—Revision]
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request; Ryan White HIV/AIDS
Program: Allocations Forms
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with of the
Paperwork Reduction Act of 1995,
HRSA submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30-day
comment period for this notice has
closed.
DATES: Comments on this ICR should be
received no later than March 10, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
8295
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under Review—Open for
Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email
Samantha Miller, the HRSA Information
Collection Clearance Officer, at
paperwork@hrsa.gov or call 301–594–
4394.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Ryan White HIV/AIDS Program:
Allocations Forms, OMB No. 0915–
0318—Revision.
Abstract: HRSA administers the Ryan
White HIV/AIDS Program (RWHAP)
authorized under Title XXVI of the
Public Health Service Act. The RWHAP
Allocations and Expenditures Reports
(A&E Reports) allow HRSA to monitor
and track the use of grant funds for
compliance with program and grants
policies, and requirements as outlined
in the legislation. To avoid duplication
and reduce recipient reporting burden,
HRSA created an electronic grantee
contract management system (GCMS)
that includes data required for various
reports, including the Allocations
Reports and other HRSA data reports,
such as the RWHAP Services Report.
Recipients can access GCMS year-round
to upload or manually enter data on
their service provider contractors or
subrecipients, the RWHAP core medical
and support services provided, and their
funding amounts. Data required for
Allocations Reports and other reports
are automatically prepopulated from
GCMS. Expenditures Report data are not
auto-populated in the GCMS, and are
still manually entered into the data
reporting system.
Allocations and Expenditures (A&E)
Reports
Recipients funded under RWHAP
Parts A, B, C, and D are required to
report financial data to HRSA at the
beginning (Allocations Report) and at
the end (Expenditures Report) of their
grant budget period. The A&E Reports
request information recipients already
collect, including the use of RWHAP
grant funds for core medical and
support services; and on various
program components, such as
administration, planning and
evaluation, and clinical quality
management (CQM). RWHAP Parts A
and B recipients funded under the
E:\FR\FM\08FEN1.SGM
08FEN1
8296
Federal Register / Vol. 88, No. 26 / Wednesday, February 8, 2023 / Notices
Ending the HIV Epidemic in the U.S.
(EHE) initiative are also required to
report allocations and expenditures of
the grant budget period in the EHE A&E
Reports. This allows HRSA to track and
report progress toward meeting the EHE
goals.
The reports are similar in content;
however, in the first report, recipients
document the allocation of their
RWHAP or EHE grant award at the
beginning of their grant budget period.
In the second report, recipients
document actual expenditures of their
RWHAP or EHE grant award (including
any carryover dollars) at the end of their
grant budget period.
HRSA proposes the following updates
to the RWHAP Allocations Reports.
RWHAP Part A Allocations Report
• Revising row and column headers
and other language for clarity and
alignment with RWHAP requirements;
• Combining the columns for RWHAP
Part A Formula and Supplemental
Allocation amounts and updating the
title;
• Moving the RWHAP Part A
Minority AIDS Initiative (MAI) Award
Amount row after the RWHAP Part A
Supplemental Award Amount row;
• Changing the calculation for Service
Allocation Subtotal percent in the Total
RWHAP Part A Allocation Amounts
column;
• Blacking out the percent columns
for the RWHAP Part A Formula and
Supplemental Allocation Amounts,
RWHAP Part A MAI Allocation
Amounts, and selected cells in the Total
RWHAP Part A Allocation Amounts
column; and
• Adding the Legislative
Requirements Checklist.
RWHAP Part B Allocations Report
RWHAP Part C Allocations Report
• Revising row and column headers
and other language for clarity and
alignment with RWHAP requirements;
• Adding the following rows to Table
1: 4c. Part B HIV Care Consortia
Planning & Evaluation/Emerging
Communities (EC) HIV Care Consortia
Planning & Evaluation and 4d. Part B
HIV Care Consortia CQM/EC HIV Care
Consortia CQM except for the AIDS
Drug Assistance Program (ADAP)
Earmark + ADAP Supplemental Award
cells;
• Removing row 11. Total Part B X07
Allocations;
• Allowing users to enter data in
Table 2 for 1d. Health Insurance
Premium & Cost Sharing and 1e. Home
and Community-based Health Services;
• Blacking out selected cells in the
following rows, columns, or tables:
D 2. Part B Health Insurance Premium &
Cost Sharing Assistance for LowIncome Individuals (Table 1) as this
information is also reported in Table
2
D 3. Part B Home and Community-based
Health Services (Table 1) as this
information is also reported in Table
2
D 4. Total Column (Table 1)
D 1a. ADAP Treatments (Table 2) as this
information is also reported in Table
1
D MAI Award (Table 3)
• Updating calculations and language
in the Legislative Requirements
Checklist; and
• Removing the following services
under the Legislative Requirements
Checklist’s Core Medical Services:
D Health Insurance Premium & Cost
Sharing Assistance, and
D Home and Community-based Health
Services.
• There are no proposed changes to
the RWHAP Part C Allocations Report.
RWHAP Part D Allocations Report
• There are no proposed changes to
the RWHAP Part D Allocations Report.
HRSA EHE Initiative A&E Reports
• There are no proposed changes to
the HRSA EHE Allocations Reports. A
60-day notice published in the Federal
Register, 87 FR pp. 71339–40
(November 22, 2022). There were no
public comments.
Need and Proposed Use of the
Information: Accurate allocation,
expenditure, and service contract
records of the recipients receiving
RWHAP and EHE funding are critical to
the implementation of the RWHAP
legislation and EHE initiative
appropriation language and thus are
necessary for HRSA to fulfill its
monitoring and oversight
responsibilities.
Likely Respondents: RWHAP Part A,
Part B, Part C, and Part D recipients.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
lotter on DSK11XQN23PROD with NOTICES1
Form name
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Part A Allocations Report ....................................................
Part B Allocations Report ....................................................
Part C Allocations Report ....................................................
Part D Allocations Report ....................................................
EHE Allocations Reports .....................................................
52
54
346
116
47
1
1
1
1
1
52
54
346
116
47
4
6
4
4
4
208
324
1,384
464
188
Total ..............................................................................
615
........................
........................
........................
2,568
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
VerDate Sep<11>2014
16:59 Feb 07, 2023
Jkt 259001
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
use of automated collection techniques
or other forms of information
E:\FR\FM\08FEN1.SGM
08FEN1
Federal Register / Vol. 88, No. 26 / Wednesday, February 8, 2023 / Notices
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–02686 Filed 2–7–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Addiction Risks and
Mechanisms Study Section, February
23, 2023, 9:00 a.m. to February 24, 2023,
7:30 p.m., Darcy Hotel, 1515 Rhode
Island Avenue, Washington, DC 20005
which was published in the Federal
Register on January 26, 2023, 88 FR
5010.
This meeting is being amended to
change the name of the hotel from Darcy
Hotel, 1515 Rhode Island Avenue,
Washington, DC 20005 to the Hotel
George, 15 E Street NW, Washington,
DC 20001. The meeting is closed to the
public.
Dated: February 3, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–02675 Filed 2–7–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
VerDate Sep<11>2014
16:59 Feb 07, 2023
Jkt 259001
Date: March 7–8, 2023.
Time: 8:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, 7400
Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Alexander Gubin, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4196,
MSC 7812, Bethesda, MD 20892, 301–435–
2902, gubina@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Health Services Research.
Date: March 7–8, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mary Kate Baker, DRPH,
Scientific Review Officer, The Center for
Scientific Review, The National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, 301–594–5117, katie.baker2@nih.gov.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel; Special:
Modern Equipment for Shared-use
Biomedical Research Facilities.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Frederique Yiannikouris,
Ph.D., Scientific Review Officer, The Center
for Scientific Review, The National Institutes
of Health, 6701 Rockledge Drive, Bethesda,
MD 20892, 301–594–3313,
frederique.yiannikouris@nih.gov.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel; Therapeutic
Immune Regulation.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Yue Wu, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 803C, Bethesda, MD 20892,
(301) 867–5309, wuy25@csr.nih.gov.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel;
Fellowships: Epidemiology and Population
Sciences.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Erin Harrell, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000G,
Bethesda, MD 20892, (301) 594–4935,
harreller@csr.nih.gov.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
8297
Name of Committee: Center for Scientific
Review, Special Emphasis Panel; Small
Business: The Cardiovascular and
Hematological Sciences.
Date: March 9–10, 2023.
Time: 9:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dmitri V Gnatenko, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 867–5309, gnatenkod2@nih.gov.
Name of Committee: Center for Scientific
Review, Special Emphasis Panel;
Fellowships: Brain Disorders and Related
Neurosciences.
Date: March 9–10, 2023.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Vilen A Movsesyan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040M,
MSC 7806, Bethesda, MD 20892, 301–402–
7278, movsesyanv@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Cellular and Molecular
Biology of Neurodegeneration Study Section.
Date: March 9–10, 2023.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Laurent Taupenot, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4188,
MSC 7850, Bethesda, MD 20892, 301–435–
1203, laurent.taupenot@nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Maximizing Investigators’
Research Award B Study Section.
Date: March 9–10, 2023.
Time: 9:30 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sudha Veeraraghavan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7846, Bethesda, MD 20892, (301) 827–
5263, sudha.veeraraghavan@nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
HIV/AIDS Intra- and Inter-personal
Determinants and Behavioral Interventions
Study Section.
Date: March 9–10, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 88, Number 26 (Wednesday, February 8, 2023)]
[Notices]
[Pages 8295-8297]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-02686]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
[OMB No. 0915-0318--Revision]
Agency Information Collection Activities: Submission to OMB for
Review and Approval; Public Comment Request; Ryan White HIV/AIDS
Program: Allocations Forms
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with of the Paperwork Reduction Act of 1995,
HRSA submitted an Information Collection Request (ICR) to the Office of
Management and Budget (OMB) for review and approval. Comments submitted
during the first public review of this ICR will be provided to OMB. OMB
will accept further comments from the public during the review and
approval period. OMB may act on HRSA's ICR only after the 30-day
comment period for this notice has closed.
DATES: Comments on this ICR should be received no later than March 10,
2023.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under Review--Open for
Public Comments'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email Samantha Miller, the HRSA
Information Collection Clearance Officer, at [email protected] or call
301-594-4394.
SUPPLEMENTARY INFORMATION: When submitting comments or requesting
information, please include the ICR title for reference.
Information Collection Request Title: Ryan White HIV/AIDS Program:
Allocations Forms, OMB No. 0915-0318--Revision.
Abstract: HRSA administers the Ryan White HIV/AIDS Program (RWHAP)
authorized under Title XXVI of the Public Health Service Act. The RWHAP
Allocations and Expenditures Reports (A&E Reports) allow HRSA to
monitor and track the use of grant funds for compliance with program
and grants policies, and requirements as outlined in the legislation.
To avoid duplication and reduce recipient reporting burden, HRSA
created an electronic grantee contract management system (GCMS) that
includes data required for various reports, including the Allocations
Reports and other HRSA data reports, such as the RWHAP Services Report.
Recipients can access GCMS year-round to upload or manually enter data
on their service provider contractors or subrecipients, the RWHAP core
medical and support services provided, and their funding amounts. Data
required for Allocations Reports and other reports are automatically
prepopulated from GCMS. Expenditures Report data are not auto-populated
in the GCMS, and are still manually entered into the data reporting
system.
Allocations and Expenditures (A&E) Reports
Recipients funded under RWHAP Parts A, B, C, and D are required to
report financial data to HRSA at the beginning (Allocations Report) and
at the end (Expenditures Report) of their grant budget period. The A&E
Reports request information recipients already collect, including the
use of RWHAP grant funds for core medical and support services; and on
various program components, such as administration, planning and
evaluation, and clinical quality management (CQM). RWHAP Parts A and B
recipients funded under the
[[Page 8296]]
Ending the HIV Epidemic in the U.S. (EHE) initiative are also required
to report allocations and expenditures of the grant budget period in
the EHE A&E Reports. This allows HRSA to track and report progress
toward meeting the EHE goals.
The reports are similar in content; however, in the first report,
recipients document the allocation of their RWHAP or EHE grant award at
the beginning of their grant budget period. In the second report,
recipients document actual expenditures of their RWHAP or EHE grant
award (including any carryover dollars) at the end of their grant
budget period.
HRSA proposes the following updates to the RWHAP Allocations
Reports.
RWHAP Part A Allocations Report
Revising row and column headers and other language for
clarity and alignment with RWHAP requirements;
Combining the columns for RWHAP Part A Formula and
Supplemental Allocation amounts and updating the title;
Moving the RWHAP Part A Minority AIDS Initiative (MAI)
Award Amount row after the RWHAP Part A Supplemental Award Amount row;
Changing the calculation for Service Allocation Subtotal
percent in the Total RWHAP Part A Allocation Amounts column;
Blacking out the percent columns for the RWHAP Part A
Formula and Supplemental Allocation Amounts, RWHAP Part A MAI
Allocation Amounts, and selected cells in the Total RWHAP Part A
Allocation Amounts column; and
Adding the Legislative Requirements Checklist.
RWHAP Part B Allocations Report
Revising row and column headers and other language for
clarity and alignment with RWHAP requirements;
Adding the following rows to Table 1: 4c. Part B HIV Care
Consortia Planning & Evaluation/Emerging Communities (EC) HIV Care
Consortia Planning & Evaluation and 4d. Part B HIV Care Consortia CQM/
EC HIV Care Consortia CQM except for the AIDS Drug Assistance Program
(ADAP) Earmark + ADAP Supplemental Award cells;
Removing row 11. Total Part B X07 Allocations;
Allowing users to enter data in Table 2 for 1d. Health
Insurance Premium & Cost Sharing and 1e. Home and Community-based
Health Services;
Blacking out selected cells in the following rows,
columns, or tables:
[ssquf] 2. Part B Health Insurance Premium & Cost Sharing Assistance
for Low-Income Individuals (Table 1) as this information is also
reported in Table 2
[ssquf] 3. Part B Home and Community-based Health Services (Table 1) as
this information is also reported in Table 2
[ssquf] 4. Total Column (Table 1)
[ssquf] 1a. ADAP Treatments (Table 2) as this information is also
reported in Table 1
[ssquf] MAI Award (Table 3)
Updating calculations and language in the Legislative
Requirements Checklist; and
Removing the following services under the Legislative
Requirements Checklist's Core Medical Services:
[ssquf] Health Insurance Premium & Cost Sharing Assistance, and
[ssquf] Home and Community-based Health Services.
RWHAP Part C Allocations Report
There are no proposed changes to the RWHAP Part C
Allocations Report.
RWHAP Part D Allocations Report
There are no proposed changes to the RWHAP Part D
Allocations Report.
HRSA EHE Initiative A&E Reports
There are no proposed changes to the HRSA EHE Allocations
Reports. A 60-day notice published in the Federal Register, 87 FR pp.
71339-40 (November 22, 2022). There were no public comments.
Need and Proposed Use of the Information: Accurate allocation,
expenditure, and service contract records of the recipients receiving
RWHAP and EHE funding are critical to the implementation of the RWHAP
legislation and EHE initiative appropriation language and thus are
necessary for HRSA to fulfill its monitoring and oversight
responsibilities.
Likely Respondents: RWHAP Part A, Part B, Part C, and Part D
recipients.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose, or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install, and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
Total Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Part A Allocations Report....... 52 1 52 4 208
Part B Allocations Report....... 54 1 54 6 324
Part C Allocations Report....... 346 1 346 4 1,384
Part D Allocations Report....... 116 1 116 4 464
EHE Allocations Reports......... 47 1 47 4 188
-------------------------------------------------------------------------------
Total....................... 615 .............. .............. .............. 2,568
----------------------------------------------------------------------------------------------------------------
HRSA specifically requests comments on (1) the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions, (2) the accuracy of the
estimated burden, (3) ways to enhance the quality, utility, and clarity
of the information to be collected, and (4) the use of automated
collection techniques or other forms of information
[[Page 8297]]
technology to minimize the information collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023-02686 Filed 2-7-23; 8:45 am]
BILLING CODE 4165-15-P
